All News

Urologists across the country offer their opinions on high-intensity focused ultrasound.

Men who walked at a fast pace prior to prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes for men with prostate cancer.

Type of surgical approach-open or robot assisted-appears to have no effect on specific clinical outcomes in patients undergoing radical prostatectomy for high-risk prostate cancer, nor does the procedure influence the pathway subsequent therapy might follow, according to a recent study.

More than 85% of patients undergoing robot-assisted laparoscopic prostatectomy may not require opioid analgesia either immediately post-op, in hospital, or upon release, according to a recent study.

A lawsuit was filed against both the urologist and the radiologist involved in the treatment of the kidney stone, claiming that he was not informed of the abnormality on the left kidney noted on the CT scan and the recommendation for follow-up.

Both the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington in Seattle have developed a personalized tool that they say can predict the likelihood of prostate cancer overdiagnosis.

PSA screening has likely played an important role in the 40%-plus drop in prostate cancer mortality since the late 1980s, although the mortality rate for metastatic disease has remained the same, say study authors from the University of California, Davis.

The controversial oil and natural gas drilling technique called hydraulic fracturing, or fracking, uses many chemicals that can disrupt the body’s hormones, according to new research.

Signs of inflammation in a man’s prostate biopsy may indicate that he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy, according to the authors of a recently published study.

Insurance coverage has expanded for an epigenetic test for prostate cancer and percutaneous tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB).

The top 10 Urology Times articles of 2013 encompass topics including prostate biopsy, the urology work force, and PSA screening.

The latest products and services from Lambert Academic Publishing, the AUA, United Guardian, and SpryPublishing.

With a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.

Risk classification changed in more than half of prostate cancers following assessment of cell cycle progression in tumors, according to a study reported at the Society of Urologic Oncology meeting in Bethesda, MD.

In this article, we briefly review the evaluation of patients with PPI and discuss the benefits and drawbacks of conservative, pharmacologic, injection, and surgical treatments.

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.

The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”

Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”

British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.

The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.

Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score than men who ate a typical Western diet, UCLA researchers reported.

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has metastasized to the bones, according to a recent analysis.

GenomeDx Biosciences has entered into contractual agreements for diagnostic laboratory testing as a participating provider that will expand insurance coverage for the company’s Decipher test for prostate cancer.

Men with prostate cancer treated with androgen deprivation therapy had significant improvement in strength and exercise capacity following a 10-week program of physical activity, education, and support, according to a study reported at the AUA annual meeting in San Diego.

Astellas Pharma US, Inc. and Medivation, Inc. have initiated a phase IV trial to evaluate the benefit of continued treatment with enzalutamide (Xtandi) beyond disease progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Men with advanced prostate cancer had similar survival with intermittent or continuous androgen deprivation therapy, pooled data from two randomized trials showed.

Data are lacking to recommend for or against the use of vitamins, minerals, and multivitamin supplements for the prevention of cancer and cardiovascular disease, according to a new U.S. Preventive Services Task Force draft recommendation statement.

No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.